(Q45220679)

11 December 2017

title

Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors (English)

1 reference

11 December 2017

0 references

0 references

Yunzhou Yu

1

1 reference

11 December 2017

Jiyu Yu

2

1 reference

11 December 2017

Na Li

3

1 reference

11 December 2017

Shuang Wang

4

1 reference

11 December 2017

Weiyuan Yu

5

1 reference

11 December 2017

Zhiwei Sun

6

1 reference

11 December 2017

language of work or name

English

0 references

publication date

25 August 2009

1 reference

11 December 2017

1 reference

11 December 2017

volume

27

1 reference

11 December 2017

issue

44

1 reference

11 December 2017

page(s)

6148-6153

1 reference

Neurotoxins affecting neuroexocytosis

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Botulinum and tetanus neurotoxins: structure, function and therapeutic utility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Development of vaccines for prevention of botulism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Botulinum neurotoxin vaccines: past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Development of recombinant vaccines for botulinum neurotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Subunit vaccine against the seven serotypes of botulism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

DNA vaccination protects against botulinum neurotoxin type F

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

High-level expression of the Hcc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Rapid, high level protein production using DNA-based Semliki Forest virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Enhancing immune responses using suicidal DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.022

10.1016/J.VACCINE.2009.08.022

7 January 2021

Identifiers

DOI

1 reference

11 December 2017

1 reference